A detailed history of Allworth Financial LP transactions in Dexcom Inc stock. As of the latest transaction made, Allworth Financial LP holds 672 shares of DXCM stock, worth $53,786. This represents 0.0% of its overall portfolio holdings.

Number of Shares
672
Previous 1,531 56.11%
Holding current value
$53,786
Previous $173,000 73.99%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$64.0 - $116.06 $54,976 - $99,695
-859 Reduced 56.11%
672 $45,000
Q2 2024

Jul 23, 2024

BUY
$110.31 - $140.45 $23,606 - $30,056
214 Added 16.25%
1,531 $173,000
Q1 2024

Apr 25, 2024

BUY
$114.22 - $140.1 $26,841 - $32,923
235 Added 21.72%
1,317 $182,000
Q4 2023

Jan 24, 2024

BUY
$75.49 - $124.16 $3,397 - $5,587
45 Added 4.34%
1,082 $134,000
Q3 2023

Oct 31, 2023

SELL
$86.06 - $137.93 $2,753 - $4,413
-32 Reduced 2.99%
1,037 $96,000
Q2 2023

Jul 18, 2023

SELL
$112.47 - $130.98 $21,481 - $25,017
-191 Reduced 15.16%
1,069 $137,000
Q1 2023

Apr 18, 2023

BUY
$104.0 - $122.92 $31,824 - $37,613
306 Added 32.08%
1,260 $146,000
Q4 2022

Jan 13, 2023

BUY
$84.98 - $122.67 $5,608 - $8,096
66 Added 7.43%
954 $0
Q3 2022

Oct 18, 2022

BUY
$76.35 - $94.18 $51,307 - $63,288
672 Added 311.11%
888 $72,000
Q2 2022

Jul 13, 2022

BUY
$67.99 - $132.89 $2,515 - $4,916
37 Added 20.67%
216 $16,000
Q1 2022

Apr 22, 2022

BUY
$94.08 - $130.2 $14,300 - $19,790
152 Added 562.96%
179 $92,000
Q4 2021

Jan 21, 2022

SELL
$129.87 - $162.82 $1,038 - $1,302
-8 Reduced 22.86%
27 $14,000
Q3 2021

Nov 02, 2021

BUY
$106.71 - $143.18 $3,734 - $5,011
35 New
35 $19,000
Q2 2021

Aug 02, 2021

SELL
$80.99 - $107.93 $242 - $323
-3 Closed
0 $0
Q4 2019

Jan 16, 2020

BUY
$36.62 - $57.29 $109 - $171
3 New
3 $1,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $30.9B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.